ASAnja Smits

Anja Smits

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anja Smits has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 28 June 2012
      • Vol. 109  (19) , 970

    [The Swedish Neurological Association: The number of neurologists need to double over the next decade].

    by Ingela Nilsson Remahl, Sten Fredrikson, Martin Gunnarsson, Albert Hietala, Lars Stridh, Katarina Jood, Joachim Burman, Rune Johansson, Svend Marup Jensen, Jesper Petersson, et al.

  • Epileptic seizures and survival in early disease of grade 2 gliomas

    by T. Danfors, D. Ribom, S. G. Berntsson, A. Smits

    Background and purpose: The aims of this study were (i) to determine the correlation between seizure activity and the metabolic rate of the tumour measured by 11C‐methionine PET (MET PET) in patients with grade 2 gliomas, and (ii) to assess the prognostic impact of early seizure manifestations on patient survival. Methods: In this retrospective review, early seizure manifestations were studied in 101 patients with supratentorial grade 2 gliomas subjected to MET PET as part of the pre‐treatment tumour investigation. Seizure manifestations as a variable was then used in multivariate survival analyses, together with established prognostic factors for this patient group. Results: Of all 101 cases, 88 patients had seizures at tumour presentation. Forty‐seven were seizure free at the early stage of the disease, whereas 54 had recurrent seizures. Patients with seizures at tumour presentation had a more favourable outcome before and after (P = 0.006) adjustment for conventional prognostic factors. However, for those who continued to have seizures early in the disease, the outcome was worse (P = 0.003). We found no significant correlation between MET PET and the seizure manifestations of the patients. Conclusion: The presence and termination of early seizure manifestations may be favourable prognostic factors in patients with low‐grade gliomas.


    • 4 October 2008
      • Vol. 105  (36) , 2413-6

    [Changing neurology--from diagnostic to therapeutic discipline].

    by Anja Smits, Gunnar Andsberg, Peter M Andersen, Magnus Andersson, Sten Fredrikson, Martin Gunnarsson, Eva Kumlien, Jan Lycke, Svend Marup Jensen, Ingela Nilsson Remahl, et al.


    • 4 October 2008
      • Vol. 105  (36) , 2428-9

    [Representantives of the Swedish Neurological Association: Swedish neurology needs strong resource reinforcement].

    by Anja Smits, Peter M Andersen, Magnus Andersson, Gunnar Andsberg, Sten Fredrikson, Martin Gunnarsson, Margareta Hultgren, Anne-Marie Landtblom, Jan Lycke, Svend Marup Jensen, et al.

  • Molecular Genetic Analysis of p53 Intratumoral Heterogeneity in Human Astrocytic Brain Tumors

    by Zhi-Ping Ren, Tommie Olofsson, Mingqi Qu, Göran Hesselager, Thierry Soussi, Hannu Kalimo, Anja Smits, Monica Nistér

    We investigated genetic heterogeneity of astrocytic gliomas using p53 gene mutations as a marker. Different parts of morphologically heterogeneous astrocytic gliomas were microdissected, and direct DNA sequencing of p53 gene exons 5 through 8 was performed. Thirty-five glioma samples and tumor-adjacent normal-appearing brain tissue from 11 patients were analyzed. Sixteen different p53 gene mutations were found in 7 patients. We found that some tumors were devoid of p53 gene mutations, whereas other tumors carried 1 or often several (up to 3) different mutations. The mutations were present in grade II, III, and IV astrocytic glioma areas. Both severe functionally dead mutants and mutants with remaining transcriptional activity could be observed in the same tumor. We observed that morphologically different parts of a glioma could carry different or similar mutations in the p53 gene and could be either associated or not associated with the locus of heterozygosity at the mutant site. Coexistence of p53 gene mutations and the locus of heterozygosity was common, at least in astrocytomas grade III and in glioblastomas, and also occurred in astrocytoma grade II areas. These results support the notion that intratumoral heterogeneity in brain tumors originates from different molecular defects. Our results are of importance for a further understanding of the molecular mechanisms behind failure to treat glioma patients.


    • 3 March 2007
      • Vol. 104  (5) , 326-30

    [MET-PET in low-grade glioma. Safe way to follow disease progression and treatment].

    by Anja Smits, Irina Savitcheva, Dan Ribom

  • Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas

    by Mingqi Qu, Tommie Olofsson, Sunna Sigurdardottir, Chao You, Hannu Kalimo, Monica Nistér, Anja Smits, Zhi-Ping Ren

    Oligoastrocytomas are glial tumours consisting of a mixture of neoplastic astrocytic and oligodendroglial cells. Genetic alterations of oligoastrocytomas include loss of heterozygosity of chromosomes 1p and/or 19q (LOH 1p/19q), typically occurring in oligodendrogliomas, and mutations of TP53, frequently occurring in astrocytomas. To investigate whether these neoplastic cell types in oligoastrocytomas have different genetic profiles, we examined the two different components of oligoastrocytomas in comparison with the histological diagnosis of the specific tumour area for LOH 1p/19q and TP53 mutations by using microdissection technique. We found a variety of lost markers for 1p and 19q, and the presence of two different TP53 mutations in the tumour samples. In the majority of cases (9/11), the oligodendroglial and astrocytic components of an individual oligoastrocytoma displayed the same genotype. We present two cases of biphasic oligoastrocytomas with aberrant findings, suggesting the coexistence of genetically and morphologically distinct tumour cell clones in these tumours. In one case, the oligodendroglial part of the tumour showed LOH19q, whereas the astrocytic part showed TP53 mutation (codon 273). In another case, we found LOH 1p/19q in the oligodendroglial component, but two retained areas on chromosome 1p in the astrocytic component of the tumour. No evidence was found for the coexistence of tumour cells with the two genotypical changes within the same morphological region of one individual tumour. The two cases of biphasic oligoastrocytomas in our sample that display a different genotype in the astrocytic and oligodendroglial part of the tumour show that different components of an oligoastrocytoma may be derived from different cell clones during neoplastic transformation.


  • Low-grade gliomas: clinical and pathobiological aspects.

    by A Smits

    The optimal management of patients with low-grade gliomas remains a challenge for the treating physician. The natural history of the disease shows a large variety, and there is a substantial controversy about many of everyday treatment recommendations. However, new developments in clinical and basic research in neuro-oncology have occurred during the last years. In this review some of these new insights into clinical and biological aspects of low-grade gliomas are discussed, with focus on the translation of new knowledge from basic research into clinical practice. For example, molecular genetic profiling of tumour material has started to guide treatment recommendations and clinical management of some patients with oligodendrogliomas. Experimental studies of the different molecular pathways in tumour cells and in their normal counterparts involved in cell-cycle check-point control have elucidated some of the underlying mechanisms of resistance of gliomas to radiotherapy and chemotherapy. Finally, improved classification of the different subtypes of low-grade gliomas may be achieved in the near future by characterization of the genetic heterogeneity within the tumour and by identification of a putative stem cell as the origin of the tumour cells.


    • 6 September 2000
      • Vol. 97  (36) , 3886-90

    [Risk of increased malignancy a reason for follow-up of low malignancy grade glioma. Early identification of high-risk patients is the key to good care].

    by A Smits, D Ribom

    Management of patients with low-grade gliomas remains a challenge. Controversies exist regarding the value of surgery and radiotherapy as well as the right timing of these treatments with respect to disease course. Several factors have been shown to have a positive correlation with better outcome, involving tumor size and localization, age and clinical condition of the patient on presentation, and epileptic seizures as a single symptom. The absence of contrast enhancement on CT-scans is also a favorable prognostic factor. Taking into account the results of these studies as well as our own experience, we suggest some strategies for the management of patients with low-grade gliomas. The importance of identifying "high-risk" patients by systematic clinical and radiological follow-up is discussed.